Automate Your Wheel Strategy on BCTXW
With Tiblio's Option Bot, you can configure your own wheel strategy including BCTXW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCTXW
- Rev/Share 0.0
- Book/Share 3196.6534
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 3.4141
- ROIC -1.9271
- MktCap 139576.0
- FreeCF/Share -6444.5711
- PFCF -0.0058
- PE -0.0
- Debt/Assets 0.0
- DivYield 0
- ROE -4.3972
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About BriaCell Therapeutics Corp. (BCTXW)
- IPO Date 2012-08-13
- Website https://briacell.com
- Industry Biotechnology
- CEO William V. Williams FCPA,
- Employees 16
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.